ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 118,08
0,32%
Dow Jones
39 671,04
-0,51%
DAX
18 732,95
0,27%
Brent Oil
81,625
0,12%
Bitcoin
69 675,91
0,83%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Sagiment Biosciences Inc (SGMT)

  7. Sagiment Biosciences Inc (SGMT) Actualités

SGMT Sagiment Biosciences Inc

5,08
0,00 (0,00%)
23 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Sagiment Biosciences Inc SGMT NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 5,08 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
5,08
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
15/5/202414:05EDGAR2Form 8-K - Current report
15/5/202413:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/5/202422:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
06/5/202414:06EDGAR2Form 8-K - Current report
25/3/202412:00GLOBESagimet Biosciences Announces Appointment of Tim Walbert and..
25/3/202411:15GLOBESagimet Biosciences Reports Full Year 2023 Financial Results..
29/2/202414:00GLOBESagimet Biosciences to Participate in Two Upcoming Investor..
15/2/202400:10EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202422:37EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/2/202422:34EDGAR2Form SC 13G - Statement of acquisition of beneficial..
02/2/202422:36EDGAR2Form 8-K - Current report
02/2/202422:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
31/1/202422:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202422:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202422:05EDGAR2Form 8-K - Current report
26/1/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
26/1/202402:58GLOBESagimet Biosciences Announces Pricing of Public Offering of..
24/1/202412:10EDGAR2Form 8-K - Current report
24/1/202412:08EDGAR2Form S-1/A - General form for registration of securities..
23/1/202423:45GLOBESagimet Biosciences Announces Proposed Public Offering of..
23/1/202423:31EDGAR2Form S-1 - General form for registration of securities under..
22/1/202414:00EDGAR2Form 8-K - Current report
22/1/202413:00GLOBESagimet Biosciences Announces Positive Topline Results from..
29/12/202322:16EDGAR2Form 8-K - Current report
08/12/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/12/202314:00GLOBESagimet Biosciences to Participate in the First Annual..
28/11/202314:00GLOBESagimet Biosciences Announces Oral Presentation of..
22/11/202314:00GLOBESagimet Biosciences to Present at the 35th Annual Piper..
21/11/202322:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202322:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202303:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202314:40EDGAR2Form 8-K - Current report
13/11/202314:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202314:00GLOBESagimet Biosciences Reports Third Quarter 2023 Financial..
10/11/202314:30GLOBESagimet Biosciences Presents Preclinical Results Supporting..
24/10/202317:00GLOBESagimet Biosciences Announces Acceptance of Two Abstracts at..
23/10/202314:00EDGAR2Form 8-K - Current report
18/10/202322:05GLOBESagimet Biosciences To Present at the H.C. Wainwright 7th..
27/9/202322:32EDGAR2Form 8-K - Current report
27/9/202322:05GLOBESagimet Biosciences Announces Completion of Enrollment of..
08/9/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202322:09EDGAR2Form 8-K - Current report
21/8/202322:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
21/8/202322:02GLOBESagimet Biosciences Reports Second Quarter 2023 Financial..
15/8/202322:04GLOBESagimet Biosciences Announces Closing of Underwriters’..
10/8/202314:14EDGAR2Form 8-K - Current report
20/7/202322:05GLOBESagimet Biosciences Announces Leadership Changes
14/7/202303:10GLOBESagimet Biosciences Announces Pricing of Upsized Initial..
23/6/202308:30GLOBESagimet Biosciences Presents Positive Phase 2b FASCINATE-2..

Dernières Valeurs Consultées

NASDAQ
SGMT
Sagiment Biosciences
BIT
P1XQE1
NLBNPIT1XQE1 20240620 36...
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés